证券代码：603639 证券简称：海利尔 公告编号：2023-044 海利尔药业集团股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 (二) 股东大会召开的地点：青岛市城阳区国城路 216 号公司五楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 13 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 224,273,962 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 65.9182 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长葛尧伦先生因出差在外无法出席本 次会议，经过半数以上董事推举董事葛家成先生代为主持会议。会议采取现场投 票及网络投票相结合的方式召开并表决。其中：出席本次股东大会现场会议的股 东 ...

海利尔药业集团股份有限公司 2023 年第一次临时股东大会 会议材料 二〇二三年八月二十五日 （一）会议类型和届次：2023 年第一次临时股东大会 （二）会议召开时间、地点： 会议时间：2023 年 8 月 25 日 14:30-16:00 会议地点：青岛市城阳区国城路 216 号五楼会议室 （三）会议出席人员 1、股东、股东代表 2、公司董事、监事和高级管理人员 3、公司聘请的律师 4、其他人员 （一）全体与会股东或股东代表、列席会议的董事、监事、高级管理人员签到； （二）报告会议出席情况，宣布会议开始； （三）本次股东大会各项议案宣读并审议； （四）股东或股东代表发言及公司董事、监事、高级管理人员回答提问； （五）记名投票表决（由股东、监事及律师组成的表决统计小组进行统计）； （六）与会代表休息（工作人员统计现场投票结果），等待接收网络投票结果； （七）网络投票结果产生后，宣读投票结果和决议； （八）律师宣读本次股东大会法律意见书，董事在股东大会决议及会议记录上签字； （九）宣布会议结束。 海利尔药业集团股份有限公司 2023 年第一次临时股东大会会议须知 为了维护海利尔药业集团股份有限公司（以下简称"公 ...

证券代码：海利尔 证券简称：603639 公告编号：2023-029 海利尔药业集团股份有限公司 关于召开2022年度暨2023年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 会议召开方式：上证路演中心网络互动 投资者可于2023年05月22日(星期一) 至05月26日(星期五)16:00前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱hailir@hailir.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 海利尔药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 05 月 29 日 下午 16:00-17:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果及 财务指标的具体情况与投 ...

Financial Performance - The company's operating revenue for 2022 reached ¥4,534,999,014.48, representing a 22.60% increase compared to ¥3,698,878,563.93 in 2021[24]. - The net profit attributable to shareholders for 2022 was ¥460,009,892.48, a 2.28% increase from ¥449,745,299.66 in 2021[24]. - The net cash flow from operating activities increased by 58.45% to ¥694,685,709.15 in 2022, up from ¥438,414,771.60 in 2021[25]. - Total assets at the end of 2022 were ¥5,837,602,158.84, a 13.57% increase from ¥5,140,249,797.15 at the end of 2021[25]. - The basic earnings per share for 2022 was ¥1.35, slightly up from ¥1.33 in 2021, marking a 1.50% increase[26]. - The diluted earnings per share also stood at ¥1.35 for 2022, consistent with the previous year[26]. - The weighted average return on equity decreased to 14.83% in 2022 from 15.93% in 2021, a reduction of 1.10 percentage points[26]. - The net assets attributable to shareholders increased to ¥3,211,952,919.85 at the end of 2022, a 5.65% rise from ¥3,040,203,246.83 at the end of 2021[25]. Dividend Policy - The company plans to distribute a cash dividend of 10 CNY per 10 shares to all shareholders, subject to approval at the shareholders' meeting[6]. - The total cash dividend amount for the fiscal year is 340,230,446.00 RMB, which represents 73.96% of the net profit attributable to ordinary shareholders in the consolidated financial statements[198]. - The company has a fixed cash dividend policy, distributing at least 10% of the distributable profits in a single fiscal year, with higher percentages based on the company's development stage and capital expenditure plans[193][194]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company has a comprehensive risk management strategy in place to address potential operational risks[8]. - The company faces risks related to safety production and environmental protection, particularly due to the nature of its chemical products[150]. - The company is addressing the volatility of raw material prices and production instability by increasing investment in technological upgrades and monitoring raw material price trends[152]. - The company is enhancing procurement strategies to mitigate risks associated with upstream raw material supply and price fluctuations[153]. Research and Development - The company is focused on expanding its market presence and enhancing its research and development capabilities for new products[18]. - Research and development expenses increased by 43.31% to CNY 234,055.75 million, reflecting a focus on new project development[64]. - The company is committed to increasing R&D investment to develop differentiated, environmentally friendly pesticide formulations to combat market competition[155]. - The company aims to enhance its R&D capabilities, aiming to build a first-class R&D team and develop forward-looking new compounds[139]. - The company has filed over 80 patents and 104 trademarks, receiving the highest honor for intellectual property management from the state[101]. Market Expansion - The company is actively exploring international markets to mitigate risks and create new growth points through diversified product offerings[44]. - The company is expanding its overseas market presence, having obtained nearly 1,800 product registration certificates in over 30 countries, including Paraguay and Egypt[60]. - The company is focusing on international market expansion, enhancing brand effect, and improving sales channels for self-produced raw materials and strategic products[147]. Production and Operations - The company produced 48,047.32 tons of pesticides, with a sales volume of 46,912.43 tons, indicating a production increase of 7.42%[69]. - The company has ongoing projects expected to complete by December 2023 and 2027, including a 20,000-ton and a 50,000-ton pesticide formulation project[114]. - The design capacity for pesticide production is 80,400 tons, with a current utilization rate of 60%[114]. - The company has completed the trial production of a new 3,000-ton pesticide project, with ongoing adjustments and upgrades to production processes[115]. Corporate Governance - The company has established a robust corporate governance structure, ensuring compliance with relevant laws and regulations to protect shareholder rights[160]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of at least one-third independence[161]. - The company has a total of 8 independent directors, contributing to governance and oversight[169]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 607.81 million yuan[175]. Employee Management - The total number of employees in the parent company is 596, while the total number of employees in major subsidiaries is 2,296, resulting in a combined total of 2,892 employees[189]. - The company has implemented a stock incentive policy to share the results of corporate development with employees[190]. - The company maintains a salary policy that emphasizes strategic orientation, internal fairness, and external competitiveness[190]. - The company has implemented a talent training program, focusing on new employees and key positions, to enhance professional skills and career development[191].

[Financial Summary and Operating Analysis](index=1&type=section&id=Item%201.%20Key%20Financial%20Data) This section details the company's core financial performance, non-recurring items, and the underlying reasons for significant financial metric fluctuations [Core Financial Indicators](index=1&type=section&id=Item%201.%281%29%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In Q1 2023, the company reported operating revenue of 1.23 billion Yuan and net profit of 152 million Yuan, with total assets reaching 6.205 billion Yuan, indicating stable growth Key Financial Data for Q1 2023 | Indicator | Current Period (Yuan) | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 1,229,872,265.99 | 2.51% | | Net Profit Attributable to Shareholders | 152,156,390.34 | 6.69% | | Net Cash Flow from Operating Activities | 147,905,383.19 | N/A | | Basic Earnings Per Share (Yuan/share) | 0.45 | 6.43% | | **Indicator** | **End of Current Period (Yuan)** | **Change from Prior Year-End (%)** | | Total Assets | 6,204,612,121.46 | 6.29% | | Owners' Equity Attributable to Shareholders | 3,372,103,540.07 | 4.99% | [Non-recurring Gains and Losses Analysis](index=2&type=section&id=Item%201.%282%29%20Non-recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During the reporting period, the company's non-recurring gains and losses totaled 3.16 million Yuan, primarily from government grants and fair value changes Details of Non-recurring Gains and Losses | Item | Amount (Yuan) | | :--- | :--- | | Government Grants Recognized in Current P&L | 5,133,430.67 | | Fair Value Changes from Financial Assets Held for Trading | 528,649.75 | | Gains/Losses on Disposal of Non-current Assets | -314,293.25 | | Other Non-operating Income and Expenses | -1,355,807.94 | | **Total** | **3,157,537.21** | [Reasons for Major Financial Indicator Changes](index=3&type=section&id=Item%201.%283%29%20Changes%20and%20Reasons%20for%20Major%20Accounting%20Data%20and%20Financial%20Indicators) Significant financial metric fluctuations were observed, including a 31.56% increase in accounts receivable and a 2720.59% surge in financial expenses due to exchange rate changes Major Financial Indicator Changes and Reasons | Item Name | Change (%) | Primary Reason | | :--- | :--- | :--- | | Accounts Receivable | 31.56 | Increase in receivables due to peak shipping season | | Construction in Progress | 49.42 | New construction projects | | Taxes Payable | 394.12 | Accrual of Q1 corporate income tax | | Financial Expenses | 2,720.59 | Exchange rate fluctuations impacting exchange gains/losses | | Investment Income | 1,111.79 | Difference between forward exchange settlement price and current exchange rate | | Asset Impairment Losses | 32,767.18 | Provision for impairment of raw material inventory | [Shareholder Structure and Holdings](index=4&type=section&id=Item%202.%20Shareholder%20Information) This section outlines the company's shareholder composition, including the total number of shareholders and the detailed holdings of its top shareholders [Major Shareholder Holdings](index=4&type=section&id=Item%202.%281%29%20Total%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) As of the reporting period end, the company had 10,625 common shareholders, with significant control held by the top two shareholders, Zhang Aiying and Ge Yaolun - At the end of the reporting period, the total number of common shareholders was **10,625**[11](index=11&type=chunk) Top Four Shareholder Holdings | Shareholder Name | Number of Shares Held (shares) | Shareholding Percentage (%) | Shareholder Type | | :--- | :--- | :--- | :--- | | Zhang Aiying | 127,253,000 | 37.40 | Domestic Natural Person | | Ge Yaolun | 62,010,588 | 18.23 | Domestic Natural Person | | Qingdao Heyi Investment Center (Limited Partnership) | 17,744,951 | 5.22 | Domestic Non-State-Owned Legal Person | | Ge Jiacheng | 12,725,300 | 3.74 | Domestic Natural Person | - Shareholders Zhang Aiying, Ge Yaolun, and Ge Jiacheng are parties acting in concert. Zhang Aiying has pledged **20,000,000** of her shares[11](index=11&type=chunk)[12](index=12&type=chunk) [Financial Statements](index=5&type=section&id=Item%204.%20Quarterly%20Financial%20Statements) This section presents the company's consolidated balance sheet, income statement, and cash flow statement for the reporting period [Consolidated Balance Sheet](index=5&type=section&id=Item%204.%282%29%20Financial%20Statements-Consolidated%20Balance%20Sheet) As of March 31, 2023, total assets reached 6.205 billion Yuan and total liabilities 2.833 billion Yuan, reflecting a stable and growing financial structure Key Balance Sheet Items (Yuan) | Item | March 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Total Assets** | **6,204,612,121.46** | **5,837,602,158.84** | | Total Current Assets | 3,329,924,986.41 | 2,952,025,948.79 | | Total Non-current Assets | 2,874,687,135.05 | 2,885,576,210.05 | | **Total Liabilities** | **2,832,508,581.39** | **2,625,649,238.99** | | Total Current Liabilities | 2,570,357,803.96 | 2,421,550,178.69 | | Total Non-current Liabilities | 262,150,777.43 | 204,099,060.30 | | **Total Owners' Equity** | **3,372,103,540.07** | **3,211,952,919.85** | [Consolidated Income Statement](index=8&type=section&id=Item%204.%282%29%20Financial%20Statements-Consolidated%20Income%20Statement) In Q1 2023, total operating revenue was 1.23 billion Yuan, with net profit attributable to parent company shareholders reaching 152 million Yuan, indicating stable profitability Key Income Statement Items (Yuan) | Item | Q1 2023 | Q1 2022 | | :--- | :--- | :--- | | Total Operating Revenue | 1,229,872,265.99 | 1,199,790,300.43 | | Total Operating Costs | 1,017,504,033.58 | 1,020,930,564.90 | | Of which: R&D Expenses | 64,369,603.40 | 50,018,468.83 | | Financial Expenses | 15,592,833.80 | 552,821.03 | | Operating Profit | 176,234,285.06 | 167,805,090.20 | | **Net Profit Attributable to Parent Company Shareholders** | **152,156,390.34** | **142,614,951.22** | [Consolidated Cash Flow Statement](index=10&type=section&id=Item%204.%282%29%20Financial%20Statements-Consolidated%20Cash%20Flow%20Statement) Net cash flow from operating activities significantly improved to a 148 million Yuan inflow in Q1 2023, with total cash and equivalents increasing to 650 million Yuan Key Cash Flow Statement Items (Yuan) | Item | Q1 2023 | Q1 2022 | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 147,905,383.19 | -19,665,221.37 | | Net Cash Flow from Investing Activities | 146,172,919.35 | -103,665,206.47 | | Net Cash Flow from Financing Activities | -228,046.91 | 20,002,971.70 | | Net Increase in Cash and Cash Equivalents | 287,161,646.38 | -98,763,697.61 | | Cash and Cash Equivalents at Period End | 650,129,364.93 | 414,745,217.90 |

Financial Performance - The company's operating revenue for Q3 2022 was approximately CNY 992 million, representing a year-on-year increase of 59%[5] - The net profit attributable to shareholders for the same period was approximately CNY 101 million, reflecting a growth of 22.68% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses reached approximately CNY 162 million, marking a significant increase of 102.18% year-on-year[5] - The company's basic earnings per share for Q3 2022 was CNY 0.29, up by 20.83% year-on-year[6] - Total operating revenue for the first three quarters of 2022 reached ¥3,802,550,062.12, a significant increase of 47.2% compared to ¥2,583,248,784.10 in the same period of 2021[18] - Net profit for the first three quarters of 2022 was ¥430,591,861.86, representing a 38.4% increase from ¥311,107,833.01 in the same period of 2021[19] - The company’s total comprehensive income for the third quarter of 2022 was ¥430,518,267.23, up from ¥311,108,669.27 in the same quarter of 2021[20] Cash Flow - The cash flow from operating activities for the year-to-date period was approximately CNY 303 million, showing a growth of 103.02%[6] - Cash flow from operating activities for the first three quarters of 2022 was ¥303,218,727.76, an increase of 102.3% from ¥149,356,093.59 in 2021[23] - The company reported a net cash flow from investment activities of -¥555,269,883.47 for the first three quarters of 2022, worsening from -¥226,801,530.60 in 2021[23] - The company received cash from financing activities amounting to ¥1,067,529,165.01 in the first three quarters of 2022, compared to ¥344,463,484.58 in 2021[23] - The net cash flow from financing activities was $327,499,464.15, an increase from $127,746,540.17 in the previous year, representing a growth of approximately 156%[24] Assets and Liabilities - The total assets at the end of the reporting period amounted to approximately CNY 6.39 billion, an increase of 24.34% from the end of the previous year[6] - As of September 30, 2022, the total assets of the company reached RMB 6,391,442,791.35, an increase from RMB 5,140,249,797.15 at the end of 2021, representing a growth of approximately 24.4%[16] - The company's current assets totaled RMB 3,725,035,612.34, up from RMB 2,887,036,129.95, indicating an increase of about 29.1% year-over-year[14] - The company's total liabilities increased to RMB 3,209,775,706.44 from RMB 2,100,046,550.32, which is an increase of approximately 52.9%[16] - The total equity attributable to shareholders reached RMB 3,181,667,084.91, up from RMB 3,040,203,246.83, representing an increase of about 4.7%[16] Investments and Expenses - Research and development expenses increased by 51.16%, indicating a commitment to enhancing R&D investment[10] - The company reported a significant increase in accounts receivable by 98.36%, attributed to expanded revenue scale[10] - The company experienced a 244.52% increase in short-term borrowings, primarily due to bank acceptance bill discounting[10] - The company reported a short-term loan of RMB 1,068,000,000.00, significantly higher than RMB 310,000,000.00 in the previous year, indicating a rise of approximately 244.8%[15] - Total operating costs for the first three quarters of 2022 were ¥3,180,955,439.46, up 43.6% from ¥2,214,384,949.26 in 2021[19] Cash and Equivalents - Cash and cash equivalents amounted to RMB 992,136,145.00, compared to RMB 840,958,760.09 in the previous year, reflecting a growth of approximately 17.9%[14] - The cash and cash equivalents at the end of the period reached $605,750,856.27, up from $438,218,084.92, reflecting a net increase of $92,241,940.76[24] - The impact of exchange rate changes on cash and cash equivalents was $16,793,632.32, compared to $7,688,017.05 in the previous year, showing an increase of approximately 118%[24] - The beginning balance of cash and cash equivalents was $513,508,915.51, which is higher than the previous year's balance of $380,228,964.71[24]

Financial Performance - The company reported a total revenue of 1.5 billion RMB for the first half of 2022, representing a year-on-year increase of 10%[1]. - The net profit attributable to shareholders was 300 million RMB, up 15% compared to the same period last year[1]. - The company's operating revenue for the first half of 2022 reached ¥2,810,510,771.27, representing a 43.44% increase compared to ¥1,959,312,048.32 in the same period last year[21]. - The net profit attributable to shareholders was ¥329,248,773.42, up 44.09% from ¥228,497,737.52 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥320,110,507.95, reflecting a 48.23% increase from ¥215,952,516.72 in the previous year[21]. - The company has set a performance guidance for the second half of 2022, aiming for a revenue target of 1.8 billion RMB, which would represent a 12% increase year-on-year[1]. - The company reported a total revenue of 247,277.76 million for the first half of 2022, with a net profit of 27,668.36 million[63]. - The company reported a significant increase in revenue, achieving a total of $500 million for the quarter, representing a 25% year-over-year growth[120]. - The total comprehensive income for the first half of 2022 was CNY 329,252,226.33, compared to CNY 228,499,109.40 in the same period of 2021, reflecting an increase of approximately 44%[169]. User Growth and Market Expansion - User data indicates a growth in active users by 20%, reaching 2 million users by the end of June 2022[1]. - The company is expanding its market presence in Southeast Asia, targeting a revenue growth of 30% in that region by the end of 2023[1]. - The company plans to launch three new products in the next quarter, focusing on pest control solutions, which are expected to increase market share by 5%[1]. - The company is expanding its market presence in Asia, targeting a 30% increase in market share within the next year[120]. Research and Development - Research and development expenses increased by 25%, totaling 150 million RMB, reflecting the company's commitment to innovation[1]. - The company plans to increase investment in technological upgrades and research to improve production efficiency and reduce costs, aiming to enhance the profitability of its pesticide products[66]. - The company has been recognized as a key high-tech enterprise and has established a comprehensive R&D center, enhancing its innovation capabilities[43]. - The company has entered trial production for several new products, including the second-generation neonicotinoid insecticides and the fungicide prothioconazole, indicating ongoing product development[42]. Financial Health and Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net outflow of ¥321,380,057.64 compared to a net inflow of ¥82,329,749.47 in the same period last year, marking a decrease of 490.36%[21]. - The company's cash and cash equivalents decreased by 41.98%, totaling RMB 487,896,476.77, down from RMB 840,958,760.09 at the end of the previous year[55]. - The company reported a decrease in cash and cash equivalents by CNY 161,664,277.93 in the first half of 2022, compared to an increase of CNY 116,146,409.62 in the same period of 2021[176]. - The net cash flow from operating activities for the first half of 2022 was -CNY 321,380,057.64, a decrease from CNY 82,329,749.47 in the same period of 2021[175]. Strategic Acquisitions and Investments - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's distribution network and increase sales by 10%[1]. - The company acquired a 26% stake in Shaanxi Jinxinyi Chemical Technology Co., Ltd. for RMB 6,483.50 million, enhancing its supply chain stability[51]. - The company completed the exit of equity stakes in several related parties, including Gansu Tianyi Agricultural Co., Ltd., by August 19, 2022[127]. Environmental and Social Responsibility - The company is committed to enhancing safety and environmental protection measures to mitigate risks associated with the production of hazardous materials[65]. - The company has implemented effective comprehensive treatment measures for wastewater, waste gas, and noise[93]. - The company donated 1 million yuan to support epidemic prevention efforts in Laixi, demonstrating its commitment to social responsibility[112]. - The company has adopted LDAR technology to significantly reduce leakage in production areas, enhancing its environmental protection efforts[108]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company faces risks from price fluctuations of raw materials, which can significantly impact production costs and profit margins[67]. - The company is actively monitoring changes in industry regulations and policies to ensure compliance and adapt its operations accordingly[71]. - The company emphasizes the importance of comprehensive risk management strategies to address various operational challenges, including supply chain disruptions and market competition[69].

2022 年第一季度报告 证券代码：603639 证券简称：海利尔 海利尔药业集团股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 | | --- | --- | --- | | | | 变动幅度(%) | | 营业收入 | 1,199,790,300.43 | 6.57 | | 归属于上市公司股东的净利润 | 142,614,951.22 | 8.94 | | 归属于上市公司股东的扣除非经常性 | 138,717,661.79 | 8.14 | | ...

Financial Performance - The company's operating revenue for 2021 reached approximately RMB 3.70 billion, representing a year-on-year increase of 14.62% compared to RMB 3.23 billion in 2020[23]. - The net profit attributable to shareholders for 2021 was approximately RMB 449.75 million, an increase of 10.59% from RMB 406.66 million in 2020[23]. - The basic earnings per share for 2021 was RMB 1.33, up 9.02% from RMB 1.22 in 2020[23]. - The weighted average return on equity for 2021 was 15.93%, a decrease of 0.90 percentage points from 16.83% in 2020[23]. - The net cash flow from operating activities for 2021 was approximately RMB 438.41 million, down 25.38% from RMB 587.51 million in 2020[23]. - The total assets at the end of 2021 were approximately RMB 5.14 billion, reflecting a year-on-year increase of 19.17% from RMB 4.31 billion at the end of 2020[23]. - The net assets attributable to shareholders at the end of 2021 were approximately RMB 3.04 billion, an increase of 16.21% from RMB 2.62 billion at the end of 2020[23]. - Operating profit reached 529.80 million yuan, up 13.56% from 466.55 million yuan year-on-year[51]. - The company achieved a revenue of 3,698.88 million yuan, a 14.62% increase from 3,227.19 million yuan in the previous year[51]. Dividend Policy - The company plans to distribute a cash dividend of 10 RMB per 10 shares to all shareholders, subject to approval at the shareholders' meeting[6]. - The cash dividend policy stipulates that at least 10% of the distributable profits must be allocated as cash dividends if conditions are met[176]. - The company's cash dividend distribution is contingent upon having positive distributable profits and sufficient cash flow[176]. - The company's remaining undistributed profits will be fully carried forward to the next fiscal year[179]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[9]. - The company has a comprehensive risk management strategy in place to address potential operational risks[9]. - The company faces risks related to safety production and environmental protection, necessitating comprehensive management and preventive measures[132]. - The volatility of raw material prices poses a risk to production stability, prompting the company to enhance its technological upgrades and cost management[134]. Research and Development - The company has been actively involved in research and development of new technologies to enhance product efficacy and safety[23]. - The company synthesized 1,891 new compounds and completed 72 patent applications, with 43 granted[88]. - Research and development expenses rose by 16.13% to ¥163,323,913.67, up from ¥140,643,255.53, due to an increase in R&D personnel and enhanced compensation[52]. - The total R&D investment accounted for 4.42% of the operating revenue[63]. - The company is committed to increasing R&D investment to develop differentiated, environmentally friendly pesticide formulations[138]. Market Expansion - The company plans to continue expanding its product offerings and market presence, focusing on new pesticide and chemical products[23]. - The company is actively expanding its international market presence to mitigate adverse market fluctuations and create new growth points[39]. - The company is focusing on diversifying its pesticide offerings, with several new products entering trial production in recent years[39]. - The company will focus on international market expansion, strengthening strategic partnerships with multinational companies[121]. Environmental Compliance - The company has implemented effective measures for environmental protection, achieving compliance with emission standards for waste gas and wastewater during the reporting period[192]. - The company has established various pollution prevention facilities, including RTO devices and wastewater treatment stations, which are operating normally[200]. - The company's wastewater treatment facilities include three-effect evaporators and MVR systems, ensuring compliance with environmental standards[200]. - The company is committed to environmental protection and has taken significant measures to manage emissions effectively[193]. Corporate Governance - The company has established a governance structure that ensures the independence of the board and management, with 3 out of 9 directors being independent[144]. - The company has implemented measures to ensure the legality and compliance of financial reports through the supervision of the supervisory board[145]. - The company is committed to transparent information disclosure, adhering to regulations to ensure all shareholders have equal access to information[145]. - The company has approved a restricted stock incentive plan for 2021, aimed at motivating and retaining key personnel[146]. Employee Development - The company emphasizes the importance of talent development, conducting annual training programs for new and existing employees[174]. - The company has established a talent cultivation plan targeting university graduates and key positions to enhance professional capabilities[174]. - The employee composition includes 1,175 production personnel, 686 sales personnel, 428 technical personnel, 55 financial personnel, and 394 administrative personnel[172]. - The company maintains a salary policy that emphasizes internal fairness and external competitiveness, aligning employee contributions with company performance[173].

Financial Performance - Q3 2021 revenue was CNY 623,936,735.78, a decrease of 6.23% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 82,610,095.49, an increase of 2.18% year-on-year[4] - Net profit excluding non-recurring items was CNY 80,234,629.65, up 26.02% from the previous year[4] - Basic earnings per share were CNY 0.24, down 4.00% year-on-year[4] - The total operating revenue for the first three quarters of 2021 reached RMB 2,583,248,784.10, slightly up from RMB 2,572,088,111.67 in the same period of 2020, indicating a growth of approximately 0.07%[18] - The total operating revenue for Q3 2021 was approximately CNY 2.58 billion, a slight increase from CNY 2.57 billion in Q3 2020, representing a growth of 0.06%[19] - The total operating costs for Q3 2021 were CNY 2.21 billion, up from CNY 2.18 billion in Q3 2020, indicating an increase of 1.03%[19] - The net profit for Q3 2021 was CNY 311.11 million, a decrease of 6.56% compared to CNY 332.99 million in Q3 2020[20] - The basic and diluted earnings per share for Q3 2021 were both CNY 0.92, down from CNY 1.00 in the same period last year[21] - The company reported a total comprehensive income of CNY 311.11 million for Q3 2021, down from CNY 332.99 million in Q3 2020[21] Cash Flow and Assets - Operating cash flow for the year-to-date reached CNY 149,356,093.59, an increase of 52.87%[4] - The company reported a significant increase in cash flow due to rising raw material prices and improved collection of receivables[8] - Cash and cash equivalents increased to RMB 662,373,110.51 from RMB 507,866,260.75, representing a growth of approximately 30.39%[14] - The net cash flow from operating activities for the first nine months of 2021 was CNY 149.36 million, compared to CNY 97.70 million in the same period of 2020, reflecting an increase of 52.83%[23] - The cash and cash equivalents at the end of Q3 2021 amounted to CNY 438.22 million, an increase from CNY 270.60 million at the end of Q3 2020[23] Assets and Liabilities - Total assets at the end of the period were CNY 4,591,838,205.21, a 6.46% increase from the end of the previous year[5] - As of September 30, 2021, total assets amounted to RMB 4,591,838,205.21, an increase from RMB 4,313,363,396.47 at the end of 2020, reflecting a growth of about 6.45%[16] - Current assets totaled RMB 2,637,228,655.10, showing a slight decrease from RMB 2,643,369,161.63 at the end of 2020[14] - Total liabilities stood at RMB 1,702,059,406.67, slightly up from RMB 1,697,131,813.54, reflecting a marginal increase of about 0.11%[16] - The expected liabilities increased to RMB 74,613,018.32 from RMB 20,899,828.95, representing a substantial rise of approximately 256.56%[16] Shareholder Equity - Shareholder equity attributable to the parent company was CNY 2,889,778,798.54, up 10.46% year-on-year[5] - The company's equity attributable to shareholders increased to RMB 2,889,778,798.54 from RMB 2,616,231,582.93, showing a growth of approximately 10.42%[16] - The weighted average return on equity was 2.89%, a decrease of 2.68 percentage points compared to the previous year[5] Research and Development - Research and development expenses for Q3 2021 were CNY 105.70 million, up from CNY 98.87 million in Q3 2020, marking an increase of 6.67%[19] Other Information - The company announced the implementation of new leasing standards starting in 2021, affecting the financial statements from the beginning of the year[24] - The report was released on October 28, 2021, indicating timely communication of financial performance[24] - No specific financial performance metrics or user data were disclosed in the document[24] - Future outlook and performance guidance were not provided in the content[24] - There were no mentions of new products or technology developments in the report[24] - Market expansion and acquisition strategies were not discussed in the document[24] - The document does not contain any specific numerical data or percentages related to financial performance[24] - The report does not highlight any new strategies beyond the leasing standard implementation[24] - Overall, the content lacks detailed financial insights or projections for stakeholders[24] - The company’s board of directors is responsible for the announcement and report[24]